Principal Financial Group Inc. decreased its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 7.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,604,251 shares of the biopharmaceutical company’s stock after selling 200,990 shares during the quarter. Principal Financial Group Inc. owned about 0.16% of Bristol-Myers Squibb worth $165,995,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Bristol-Myers Squibb by 0.3% during the second quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock valued at $6,611,829,000 after buying an additional 333,685 shares during the last quarter. BlackRock Inc. raised its stake in Bristol-Myers Squibb by 2.4% during the second quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock valued at $5,541,612,000 after buying an additional 2,367,864 shares during the last quarter. Dodge & Cox raised its stake in Bristol-Myers Squibb by 1.6% during the second quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock valued at $1,648,168,000 after buying an additional 459,271 shares during the last quarter. Northern Trust Corp raised its stake in Bristol-Myers Squibb by 3.9% during the second quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock valued at $1,339,612,000 after buying an additional 910,496 shares during the last quarter. Finally, Jennison Associates LLC raised its stake in Bristol-Myers Squibb by 5.4% during the second quarter. Jennison Associates LLC now owns 23,118,789 shares of the biopharmaceutical company’s stock valued at $1,288,179,000 after buying an additional 1,184,652 shares during the last quarter. Institutional investors and hedge funds own 69.80% of the company’s stock.
In related news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the sale, the executive vice president now owns 9,251 shares in the company, valued at $585,033.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by corporate insiders.
Bristol-Myers Squibb Co (NYSE:BMY) traded down $1.36 during trading on Wednesday, reaching $62.60. The company had a trading volume of 8,886,885 shares, compared to its average volume of 6,390,000. The stock has a market capitalization of $102,460.00, a PE ratio of 24.65, a PEG ratio of 2.23 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Co has a 12 month low of $48.21 and a 12 month high of $66.10.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date of this dividend is Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio is 62.99%.
A number of research analysts have issued reports on BMY shares. UBS Group reiterated a “buy” rating and set a $72.00 price objective (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Vetr upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 price target for the company in a research note on Monday, October 9th. BMO Capital Markets set a $49.00 price target on Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 12th. Barclays boosted their price target on Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a research note on Friday, October 13th. Finally, Jefferies Group cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price target for the company. in a research note on Monday, October 16th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $65.38.
COPYRIGHT VIOLATION WARNING: “Principal Financial Group Inc. Sells 200,990 Shares of Bristol-Myers Squibb Co (BMY)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/01/31/bristol-myers-squibb-co-bmy-stake-lessened-by-principal-financial-group-inc.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.